Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new Phase 3 data at the International Association for the Study of Pain 2026 World Congress on Pain, showing that TONMYA (cyclobenzaprine HCl sublingual tablets) improved both physical symptoms and functional capacity in adults with fibromyalgia. The results, drawn from the RELIEF and RESILIENT studies, carry weight because they move beyond pain scores alone to measure how patients function in daily life—a domain where fibromyalgia treatments have historically struggled to demonstrate durable benefit.
Both randomized, double-blind, placebo-controlled trials evaluated TONMYA against placebo over 14 weeks. Participants receiving TONMYA experienced statistically and clinically significant improvements in pain scores at Week 14, along with greater reductions in symptom severity and better physical functioning as measured by the Fibromyalgia Impact Questionnaire-Revised (FIQR). Improvements in FIQR symptom and function scores were observed as early as Week 2 and were sustained at Weeks 6, 10 and 14 in both studies. Week 14 results were statistically significant for both domains in RESILIENT (p≤0.001) and nominally significant in RELIEF (p<0.01).
The consistency of the functional improvements across two separate trials is significant for a condition that affects an estimated 4 million U.S. adults and for which few approved options exist. TONMYA was generally well tolerated, with no new safety signals identified; local oral administration site reactions were the most common treatment-emergent adverse events. CEO Seth Lederman said the findings reinforce the potential role of TONMYA as a first-line, non-opioid treatment option for adults with fibromyalgia—a positioning that matters as payers and clinicians seek alternatives to opioids and as patients cycle through therapies with limited efficacy.
Tonix is a fully integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments. TONMYA, the company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. The company is also maximizing the science behind TONMYA in Phase 2 trials evaluating its potential in major depressive disorder and acute stress disorder, suggesting the drug could have a broader role if those studies read out positively. Tonix's CNS commercial infrastructure supports its marketed acute migraine products, Zembrace SymTouch and Tosymra, while its pipeline includes TNX-2900 for Prader-Willi syndrome and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention.
For investors, the data presentation is a reminder that TONMYA's commercial case rests on demonstrated functional benefit, not just pain relief. Additional details are available in the full press release at https://ibn.fm/8D8UV, and ongoing updates on the company can be found through its newsroom at https://ibn.fm/TNXP. The announcement was distributed through BioMedWire, a communications platform specializing in biotechnology and life sciences that operates within the Dynamic Brand Portfolio at IBN. The platform provides wire solutions through InvestorWire, including editorial syndication to 5,000+ outlets and social media distribution.
